Compare Crispr Therapeutics AG (CRSP) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Clear Secure Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Clear Secure Inc trades at $54.42 (market cap $5.39B). The key difference: Crispr Therapeutics AG and Clear Secure Inc are close in size by market cap, and Clear Secure Inc pays a 1.12% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | YOU | |
|---|---|---|
Market Cap | $4.97B | $5.39B |
Sector | Health | Technology |
52-Week High | $76.78 | $62.36 |
52-Week Low | $44.34 | $28.84 |
Enterprise Value | $3.32B | $4.71B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Clear Secure (YOU) trades at $53.08, down 3.88% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 65.48% gross margins and impressive 81.15% ROE. Recent Q1 2026 earnings beat expectations at $0.38 EPS versus $0.35 expected, while analysts maintain a mixed consensus with 44% buy ratings and a $56.67 price target. The company continues expanding its airport security services with recent launches in Indianapolis and Miami.
YOU presents a compelling growth story with expanding revenue and profitability, though elevated valuation multiples (P/E 42.83) warrant caution. Near-term catalysts include Q2 earnings and continued airport expansion, while risks involve execution challenges and market volatility. The stock offers potential upside to analyst targets but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
